News
ABUS
3.170
-3.35%
-0.110
Weekly Report: what happened at ABUS last week (0630-0704)?
Weekly Report · 4d ago
Weekly Report: what happened at ABUS last week (0623-0627)?
Weekly Report · 06/30 09:14
Arbutus Biopharma Reacquires China Rights To Imdusiran
NASDAQ · 06/25 12:12
Arbutus Biopharma Ends Partnership with Qilu Pharmaceutical
TipRanks · 06/25 11:59
Arbutus Biopharma Reacquires Rights to Imdusiran in Greater China, Concludes Partnership with Qilu Pharmaceutical
NASDAQ · 06/25 11:41
Arbutus Biopharma reacquires Greater China rights to imdusiran, forms SAB
TipRanks · 06/25 11:35
ARBUTUS REACQUIRES GREATER CHINA RIGHTS TO IMDUSIRAN AND ANNOUNCES SCIENTIFIC ADVISORY BOARD WITH LATE-STAGE CLINICAL FOCUS
Reuters · 06/25 11:30
Weekly Report: what happened at ABUS last week (0616-0620)?
Weekly Report · 06/23 09:14
Weekly Report: what happened at ABUS last week (0609-0613)?
Weekly Report · 06/16 09:14
Weekly Report: what happened at ABUS last week (0602-0606)?
Weekly Report · 06/09 09:14
Tourlite Capital Q1 2025 Investor Letter
Seeking Alpha · 06/04 06:00
Weekly Report: what happened at ABUS last week (0526-0530)?
Weekly Report · 06/02 09:15
abrdn Life Sciences Investors Q1 2025 Commentary
Seeking Alpha · 05/31 04:20
Weekly Report: what happened at ABUS last week (0519-0523)?
Weekly Report · 05/26 09:15
Arbutus Biopharma Holds Annual Shareholder Meeting
TipRanks · 05/23 20:36
Weekly Report: what happened at ABUS last week (0512-0516)?
Weekly Report · 05/19 09:14
ARBUTUS BIOPHARMA CORPORATION FORM 10-Q
Press release · 05/14 22:12
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
NASDAQ · 05/14 12:45
Arbutus Biopharma Corp reports results for the quarter ended March 31 - Earnings Summary
Reuters · 05/14 12:31
Arbutus Biopharma Achieves Milestones in Hepatitis B Treatment and Expands Leadership
TipRanks · 05/14 12:10
More
Webull provides a variety of real-time ABUS stock news. You can receive the latest news about Arbutus Biopharm through multiple platforms. This information may help you make smarter investment decisions.
About ABUS
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.